Interference by Activated Protein C Resistance in the Determination of Protein S Activity
NCT06182501 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 9470
Last updated 2023-12-27
Summary
Protein S is an anticoagulant protein and a cofactor of protein C. It is recommended to explore it first by a functional (chronometric) technique by assessing its cofactor activity of activated protein C. Existing tests measure the prolongation of a coagulation time. These tests are all dependent on factor V, but some patients have mutations in factor V (including V Leiden) that make them resistant to activated protein C activity. It is suspected that these mutations lead to underestimations of protein S activity by chronometric technique.
Conditions
- Resistance to Activated Protein C in the Determination of Protein S Activity
Sponsors & Collaborators
-
University Hospital, Strasbourg, France
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-01
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- France
Study Locations
More Related Trials
-
The Proteins of the Contact Activation System
NCT02785718 ·Status: UNKNOWN ·Phase: NA
-
Cooperative Study of Factor VIII Inhibitors
NCT00000582 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency
NCT02470871 ·Status: COMPLETED ·Phase: PHASE1
-
Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage
NCT00770718 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
NCT00221195 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia
NCT01439971 ·Status: COMPLETED ·Phase: PHASE1
-
Severe Pregnancy Complications Are Associated With Elevated Factor VIII Plasma Activity
NCT00573118 ·Status: UNKNOWN
-
Clot Formation and Clot Stability in Patients With Severe Haemophilia A
NCT00279578 ·Status: COMPLETED ·Phase: NA
-
A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing Surgery
NCT01538160 ·Status: UNKNOWN ·Phase: NA
-
Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia
NCT01285089 ·Status: COMPLETED
-
Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
NCT01220141 ·Status: COMPLETED
-
Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation
NCT00375323 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Congenital Factor VII Deficiency
NCT01779921 ·Status: COMPLETED
-
Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
NCT05487976 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM
NCT05695391 ·Status: TERMINATED ·Phase: PHASE3
-
Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease
NCT00816660 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
NCT00108758 ·Status: COMPLETED ·Phase: PHASE2
-
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
NCT02256917 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating ReFacto in Hemophilia A
NCT00038909 ·Status: COMPLETED ·Phase: NA
-
A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture
NCT02402829 ·Status: TERMINATED
-
Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
NCT03876301 ·Status: COMPLETED
-
Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
NCT01562587 ·Status: COMPLETED ·Phase: PHASE1
-
Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors
NCT02554526 ·Status: UNKNOWN
-
Human Fibrinogen - Pharmacokinetics
NCT00496262 ·Status: COMPLETED ·Phase: PHASE2
-
Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)
NCT01579903 ·Status: COMPLETED ·Phase: PHASE1